Eli Lilly to Launch Weight-Loss Pill in India Soon

Eli Lilly is preparing to introduce Orforglipron, its experimental oral weight-loss drug, in India, after the successful launch of its injectable therapy Mounjaro (tirzepatide) earlier this year. According to company executives, regulatory applications for Orforglipron are expected within the next three months, with the second half of 2026 being the most probable time for approvals.

Patrik Jonsson, Executive Vice-President of Eli Lilly and President of Lilly International, cleared the air, “We are getting ready for our regulatory filings for chronic weight management and obesity by the end of this year. The second half of 2026 is when the approvals from a number of countries are expected.” Among the first places in the world where submissions will be made is India, with type 2 diabetes treatment applications to be filed in early 2026, as per the company’s statement.

The pharma market in India that is largely dependent on oral drugs makes Orforglipron a great fit for the adoption of the drug in the country. Eli Lilly also pointed out the comparison trial data showing that Orforglipron led to a more significant weight loss and better glucose control than Novo Nordisk's oral semaglutide, Rybelsus.

Also Read: Metropolis Acquires Kolhapur Lab to Boost Regional Reach

Through value-based pricing, Eli Lilly plans to offer therapeutic benefits to the patients at a reasonable price, thereby Orforglipron will be well placed to be embraced by the obesity care sector in India which is rapidly growing.